Polymorphisms in ADAR1 gene affect response to interferon alpha based therapy for chronic hepatitis B in Han Chinese

Antiviral Res. 2012 Jun;94(3):272-5. doi: 10.1016/j.antiviral.2012.03.004. Epub 2012 Mar 17.

Abstract

Host genetic polymorphisms in interferon pathway genes are reported to be associated with response to interferon therapy. Five hundred and forty-eight α interferon treatment-naïve chronic hepatitis B patients were enrolled in the retrospective nested case-control study. All patients received α interferon based treatment and were examined for therapy efficacy. We genotyped 115 polymorphisms from 16 interferon pathway genes using the MassArray system. We identified rs4845384 in ADAR1 gene is strongly associated with the outcome of interferon therapy allele dose-depended (P=0.0005), with decreased odds ratios of 0.69 and 0.27 for GA and AA genotypes, respectively (95% confidence interval, 0.47-0.99 for GA; 0.11-0.64 for AA). Our study suggested that rs4845384 in ADAR1 associates with treatment-induced clearance of chronic hepatitis B.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Deaminase / genetics*
  • Adolescent
  • Adult
  • Aged
  • Case-Control Studies
  • Child
  • China
  • Female
  • Hepatitis B, Chronic / drug therapy*
  • Humans
  • Immunologic Factors / therapeutic use*
  • Interferon-alpha / therapeutic use*
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • RNA-Binding Proteins
  • Retrospective Studies
  • Treatment Outcome
  • Young Adult

Substances

  • Immunologic Factors
  • Interferon-alpha
  • RNA-Binding Proteins
  • ADARB1 protein, human
  • Adenosine Deaminase